Document is current
Any future updates will be listed below
-
Authors
Fiskus, Warren https://orcid.org/0000-0002-7343-6214
Mill, Christopher P. https://orcid.org/0000-0003-0957-6009
Piel, Jessica
Collins, Mike
Hentemann, Murphy
Cuglievan, Branko
Birdwell, Christine E.
Das, Kaberi
Hou, Hanxi https://orcid.org/0000-0002-1951-3522
Davis, John A.
Jain, Antrix
Malovannaya, Anna
Kadia, Tapan M. https://orcid.org/0000-0002-9892-9832
Daver, Naval https://orcid.org/0000-0001-7103-373X
Sasaki, Koji https://orcid.org/0000-0002-9140-0610
Takahashi, Koichi https://orcid.org/0000-0002-8027-9659
Hammond, Danielle https://orcid.org/0000-0002-6017-2264
Reville, Patrick K. https://orcid.org/0000-0001-8433-3360
Flores, Lauren B.
Loghavi, Sanam https://orcid.org/0000-0001-8980-3202
Su, Xiaoping
DiNardo, Courtney D. https://orcid.org/0000-0001-9003-0390
Bhalla, Kapil N. https://orcid.org/0000-0001-5209-5126
- License Information
-
More Information
Article History
Received: 24 December 2024
Revised: 22 February 2025
Accepted: 7 March 2025
First Online: 15 March 2025
Competing interests
: KNB has received research funding from Iterion, Foghorn and Nurix Pharmaceuticals, and he serves as a consultant for Iterion Therapeutics. Jessica Piel, Mike Collins and Murphy Hentemann are employed by Foghorn Therapeutics. All other authors declare they have no conflict of interests to disclose.
